About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Tennessee | 898 Studies

Clinical Trials Lung CancerTennessee

Lung Cancer Clinical Trials in Tennessee

Find 898 clinical trials for lung cancer near Tennessee. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 141-160 of 898 trials

RecruitingStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic…NCT07680790·Beverly Hills, California and 204 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid TumorsThis is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with…NCT03854227·Scottsdale, Arizona and 21 others

CompletedStudy of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersPhase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.NCT02526017·Scottsdale, Arizona and 38 others

CompletedPhase 1/1b Study of MGCD516 in Patients With Advanced CancerMGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR…NCT02219711·Birmingham, Alabama and 42 others

RecruitingA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsThis is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity…NCT06270706·New Haven, Connecticut and 21 others

RecruitingGEMINI-NSCLC: NSCLC Biomarker StudyGEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood…NCT05236114·Birmingham, Alabama and 57 others

TerminatedA Study of Ladiratuzumab Vedotin in Advanced Solid TumorsThis trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors.NCT04032704·Chandler, Arizona and 65 others

Active not recruitingGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsThe goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without…NCT04083599·Anchorage, Alaska and 75 others

Active not recruitingA Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung CancerTo confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab…NCT05318573·Long Beach, California and 22 others

Active not recruitingA Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsTScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes…NCT05812027·Scottsdale, Arizona and 20 others

RecruitingStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsThis study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated…NCT06128551·Duarte, California and 55 others

RecruitingA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung…NCT05967689·Birmingham, Alabama and 79 others

No longer availableExpanded Treatment Protocol With LDK378 in ALK(+) NSCLCNovartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in…NCT01947608·Chandler, Arizona and 49 others

Active not recruitingAvelumab Program Rollover StudyThe main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same…NCT03815643·Scottsdale, Arizona and 103 others

RecruitingA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery.NCT07513376·Sacramento, California and 125 others

CompletedA Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsTaxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.NCT00085826·Birmingham, Alabama and 113 others

RecruitingPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsThe purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as…NCT06357533·Anchorage, Alaska and 289 others

CompletedNeurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer ClinicRATIONALE: Gathering information about how often problems with neurocognitive functioning occur in patients with newly diagnosed upper aerodigestive tract cancers may help doctors…NCT00533884·Nashville, Tennessee and 3 others

CompletedA Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung CancerThis is a study of the drug perifosine that consists of 2 parts.NCT00399789·Tucson, Arizona and 20 others

CompletedPhase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsCK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing…NCT02926768·Sarasota, Florida and 19 others

PreviousPage 8 of 45Next

Other Conditions in Tennessee

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma